Table of Contents

The court has scheduled early discovery and motion practice focused on preemption and the adequacy of warning labels in the Ozempic lawsuits. However, the issue of marketing discovery has not been fully addressed, and plaintiffs are now seeking permission to include it at this early stage through a new motion.

Plaintiffs argue that marketing discovery is essential to the case, as pharmaceutical companies may downplay or obscure risks in their marketing, which can undermine the effectiveness of warnings provided on product labels. This is particularly significant given the stakes in this litigation. There is ample precedent supporting the relevance of marketing materials in evaluating the adequacy of warnings and in challenging preemption defenses, as marketing directly influences consumer perception and usage.

Enter a 10-digit phone number with digits only (e.g., 1234567890)

By clicking the ‘Get a Free Review’ button, I hereby grant consent to be contacted at the phone number above for marketing purposes by Tort Advisor and its partners. I understand this may include an automated calling system, artificial voice, pre-recorded message, or an SMS text message. I consent even if my phone number provided is registered on the Federal or State ‘Do Not Call Registry’. I acknowledge that standard message and data rates may apply. Message frequency varies. Text HELP for help. Text STOP to cancel. Clicking ‘Get a Free Review’ constitutes my electronic signature for authorization to be contacted and my agreement to the Terms and Conditions and [Privacy Policy]. This authorization is not required to qualify for, purchase goods, or receive services.

Partners Off-Canvas (Hidden)